This HTML5 document contains 223 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33598040
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ vitskapeleg artikkel 2009년 논문 2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած научни чланак 2009年論文 2009年論文 vetenskaplig artikel บทความทางวิทยาศาสตร์ article scientific vitenskapelig artikkel articolo scientifico artikulong pang-agham vědecký článek 2009年論文 videnskabelig artikel (udgivet 2009) 2009年论文 artigo científico (publicado na 2009) articol științific naučni članak مقالهٔ علمی mokslinis straipsnis wetenschappelijk artikel artykuł naukowy επιστημονικό άρθρο мақолаи илмӣ 2009年论文 article scientifique (publié 2009) artigo científico (publicado na 2009) научна статия vedecký článok 2009年論文 наукова стаття, опублікована в жовтні 2009 artigo científico artículu científicu espublizáu en 2009 2009年论文 ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article სამეცნიერო სტატია مقالة علمية bài báo khoa học bilimsel makale scienca artikolo 2009年論文 tieteellinen artikkeli 2009年论文 wissenschaftlicher Artikel article científic научни чланак 2009 թվականի հոտեմբերին հրատարակված գիտական հոդված artikull shkencor מאמר מדעי 2009年の論文 2009年论文 artículo científico publicado en 2009 научная статья teaduslik artikkel tudományos cikk 2009 nî lūn-bûn سائنسی مضمون 2009年论文
p:P577
wds:Q33598040-C2CBB666-1A44-427C-82B7-B6E9B10B223E
wdt:P577
2009-10-27T00:00:00Z
p:P407
wds:Q33598040-6A6FB752-6B2B-4EC1-8E08-B8D7F2E0C28A
wdt:P407
wd:Q1860
p:P2860
wds:Q33598040-06F3E944-5955-46C8-93F0-6AABEFC01595 wds:Q33598040-0AF7479A-A42A-4C25-9B42-54DB7522EB81 wds:Q33598040-009D0167-593D-416F-8DA5-D17AB9684352 wds:Q33598040-E5610108-FF6A-42EF-BD47-17D6F773541E wds:Q33598040-EB5A6253-047E-47AD-93BE-3C3D30D47D9B wds:Q33598040-EC0F4A39-1E53-4520-8B19-347FA117F9F9 wds:Q33598040-F8517E3D-271D-43DE-AD5E-736E547E6AE2 wds:Q33598040-51E7CD97-6C51-47D4-8227-D26B8EDACCE9 wds:Q33598040-53DCA62D-435F-43D0-ABD7-B011B4CCB3DE wds:Q33598040-607C0B5A-0FD1-4442-88B2-407270027C5B wds:Q33598040-6F795833-11A5-43DE-9568-D98DDDB269AB wds:Q33598040-7A84BA7D-790F-4769-81C1-0B03D5407425 wds:Q33598040-6B87A11D-C270-4381-AF00-4B98A48A23A9 wds:Q33598040-1CA043BC-A737-4E26-AEF2-A32610A0896E wds:Q33598040-208B83EE-1545-449F-81B2-F4EF9A588FB6 wds:Q33598040-3146A4C2-E31A-4B97-A0AB-58A3991B1988 wds:Q33598040-10C459A3-3AEA-49D2-9998-8C2604AC312F wds:Q33598040-12F0C95E-5B07-4B6E-93A4-FD599EF633D1 wds:Q33598040-1540BC89-086C-47CE-B473-C63FB4C3D9EF wds:Q33598040-3CE42543-113C-4028-B7D4-5041024730E4 wds:Q33598040-463170EE-CB21-4F0B-B4A9-A9768DEFABBE wds:Q33598040-32735D51-4362-4644-ADB7-D5C736A4CB10 wds:Q33598040-C089C8C8-CB4F-4391-8D69-B770C3062550 wds:Q33598040-C9249C30-05C7-4088-A6E8-6DB3C974FA58 wds:Q33598040-B9024180-5744-481B-AB76-508F87F2B138 wds:Q33598040-BA7498F8-52E4-45F7-A069-921C8D56B288 wds:Q33598040-BF57C82F-969B-4A16-8200-E2179C618B43 wds:Q33598040-C047363B-3C30-41AE-A7F3-70CBA549B54F wds:Q33598040-DB0F9777-5A85-4949-A172-62239BC8A2C0 wds:Q33598040-D3FAB699-A9FF-44A6-A69B-99E30DDED049 wds:Q33598040-89D82926-E4C3-4A29-BFCD-A6F2B2E0835F wds:Q33598040-85DA21E2-32A5-4D5B-BC8B-58DD79D6CB43 wds:Q33598040-9CF7EB47-A77D-4C82-9EF4-13EC605D565A wds:Q33598040-9DD771C7-D841-4E32-B398-57D553AFAA7B wds:Q33598040-AAB2B0C0-4F3B-49FF-88F7-13FC548A5190 wds:Q33598040-91B427B3-7056-4E8A-B708-4EEB36D266CC wds:Q33598040-98F20FF0-F701-4374-A72A-CA5EB5442130
wdt:P2860
wd:Q44139578 wd:Q47881524 wd:Q37456934 wd:Q33316023 wd:Q35629356 wd:Q39730124 wd:Q36896466 wd:Q36693957 wd:Q34942985 wd:Q36748243 wd:Q34984935 wd:Q33319552 wd:Q34004431 wd:Q37294887 wd:Q34359432 wd:Q36909391 wd:Q33359552 wd:Q36862490 wd:Q48005602 wd:Q44368110 wd:Q41912941 wd:Q35513031 wd:Q27973516 wd:Q36594057 wd:Q39362584 wd:Q48065126 wd:Q33302903 wd:Q36477537 wd:Q34260722 wd:Q37459461 wd:Q37267850 wd:Q34260615 wd:Q42632486 wd:Q33788306 wd:Q36625367 wd:Q35927982 wd:Q57263834
p:P2093
wds:Q33598040-326CDB26-716B-4F58-9D22-E63BDC9670CA wds:Q33598040-7508A965-19BB-4A02-8E27-CC9D34FCBD9F
wdt:P2093
Ousmane Kante Laura B Martin
rdfs:label
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
skos:prefLabel
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
schema:name
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
p:P50
wds:Q33598040-069F6FED-FA59-4A02-A5CC-5520CF5D14E8 wds:Q33598040-3C8E5F67-788B-4B3E-8166-D5BC40B8734C wds:Q33598040-43EED291-69AA-4C39-8634-222D8698BCF5 wds:Q33598040-49C068C3-A0E3-45AD-957E-64EFE48656FA wds:Q33598040-6F490CC8-26DF-45CF-B34E-D3962CB9815F wds:Q33598040-49C9B4E3-5A02-415F-8631-1FEEDDC72E2D wds:Q33598040-4BDBF15C-1B59-410B-9507-F8F72433BCE6 wds:Q33598040-9587C90E-69B1-4A83-A183-0FCDA7CF01D5 wds:Q33598040-9AD4FEFA-A136-4A90-90E4-1F274A10EEF7 wds:Q33598040-B75291D0-C37E-46E3-8C69-16363391B07C wds:Q33598040-7E97A52D-BF48-47BB-8387-D42EFE5DCBEF wds:Q33598040-80BACC2D-4281-4D8C-968E-C0B0877051E9 wds:Q33598040-8F123674-5869-47C6-A99E-AC4DAB26F930 wds:Q33598040-CD6E97EC-4978-4B46-8242-1B374529520D wds:Q33598040-FCD379EB-7F36-4614-BF7F-6D1131F7BD34 wds:Q33598040-D898431C-1DFC-4469-8EF1-474BDC7C0694 wds:Q33598040-DC7F5046-E274-4334-B832-E627860037D6 wds:Q33598040-E2F616FC-2EE7-4F88-B54B-27972A1B4E95 wds:Q33598040-CB53E1D3-88CE-49AD-B377-7371B6A1E69F
wdt:P50
wd:Q72308308 wd:Q114406005 wd:Q72250521 wd:Q66876252 wd:Q72307944 wd:Q66908908 wd:Q47087433 wd:Q72251980 wd:Q72369361 wd:Q114406010 wd:Q3349810 wd:Q1646045 wd:Q114406008 wd:Q114406009 wd:Q114406003 wd:Q48691498 wd:Q72250716 wd:Q114406011 wd:Q88672445
p:P1476
wds:Q33598040-17CEE77A-DB28-4001-BE0A-532887E68DBA
wdt:P1476
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
p:P304
wds:Q33598040-4A6D5F90-3E48-4964-9790-BB11DF25E7CE
wdt:P304
7292-7298
p:P31
wds:Q33598040-33F2E35C-04A8-419B-A1D6-61ED0555ECB9
wdt:P31
wd:Q13442814
p:P921
wds:Q33598040-23CE7B4C-76F4-48EB-9DE9-1E25F6A37385 wds:Q33598040-0242718E-1967-4B32-9905-B4DC99FFA361 wds:Q33598040-D83EB47E-9B45-404F-A251-67E1902B2EF5 wds:Q33598040-F9E97B0D-36B4-46EF-B26A-51495C5778F4 wds:Q33598040-7D5CB78A-102A-455D-8C1C-A62FD8B0F01B
wdt:P921
wd:Q6741353 wd:Q18554672 wd:Q912 wd:Q311383 wd:Q12156
p:P698
wds:Q33598040-6520A996-BE87-422A-86A9-FEA92ABF61B9
wdtn:P698
n9:19874925
wdt:P698
19874925
p:P1433
wds:Q33598040-5B9D33D3-72CF-49CE-9AB9-6A360FE268F9
wdt:P1433
wd:Q7907941
p:P433
wds:Q33598040-724CF6A5-D80A-4141-AC5D-03A2692B67CE
p:P478
wds:Q33598040-509FA9F1-FC3F-4789-B9D3-8418ABCF2961
wdt:P433
52
wdt:P478
27
p:P356
wds:Q33598040-91235F5D-E3D0-41DF-8F36-00538F6F65D2
wdtn:P356
n11:J.VACCINE.2009.10.087
wdt:P356
10.1016/J.VACCINE.2009.10.087
p:P5875
wds:Q33598040-D03B7817-4463-415A-8C62-9F47E216F49C
wdt:P5875
38053415
p:P932
wds:Q33598040-8CEDAE9B-998A-439E-BBF9-C0B843F83C00
wdt:P932
2808270